<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The optimal antiproteinuric dose of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> is unknown </plain></SENT>
<SENT sid="1" pm="."><plain>This study compared the effect of placebo and increasing doses of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> on urinary albumin excretion rate (UAER) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The trial was a double-blind crossover design </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-six patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:mp ids='MP_0002871'>albuminuria</z:mp> were randomised to 2-month treatments with placebo or <z:chebi fb="0" ids="601027">aliskiren</z:chebi> 150 mg, 300 mg or 600 mg once daily, in random order </plain></SENT>
<SENT sid="4" pm="."><plain>Primary endpoint was change in UAER; secondary endpoints included changes in 24-h BP, GFR, biomarkers and components of the renin-angiotensin-<z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> system </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Placebo geometric mean UAER was 350 mg/day, mean 24-h BP was 137/81 (SD 12/9) mmHg, GFR was 85 (SD 26) ml min(-1) 1.73 m(-2) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="601027">Aliskiren</z:chebi> 150, 300 and 600 mg daily reduced UAER significantly by 36% (95% CI 17-51), 48% (33-60) and 52% (38-63) respectively (p &lt; 0.001) compared with placebo </plain></SENT>
<SENT sid="7" pm="."><plain>UAER reduction during the 600 mg dose was not significantly different from the 300 mg dose </plain></SENT>
<SENT sid="8" pm="."><plain>Twenty-four-hour systolic BP was reduced by 4.5, 8.0 and 9.2 mmHg versus placebo, significant for 300 and 600 mg (p &lt; or = 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Twenty-four-hour diastolic BP was reduced by 3.0, 4.1 and 4.4 mmHg, significant versus placebo (p = 0.019, p = 0.001 and p &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>GFR was reduced by 3.0, 5.1 and 6.5 ml min(-1) 1.73 m(-2) </plain></SENT>
<SENT sid="11" pm="."><plain>hsPRA was reduced by 63%, 70%, and 82% (p &lt; 0.001 for <z:hpo ids='HP_0000001'>all</z:hpo>) </plain></SENT>
<SENT sid="12" pm="."><plain>Adverse events, most frequently dizziness and <z:mp ids='MP_0002899'>fatigue</z:mp>, occurred during <z:hpo ids='HP_0000001'>all</z:hpo> doses </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: In patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:mp ids='MP_0002871'>albuminuria</z:mp> there is no improved antiproteinuric effect when using 600 mg <z:chebi fb="0" ids="601027">aliskiren</z:chebi> daily compared with the maximal recommended <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> dose of 300 mg </plain></SENT>
<SENT sid="14" pm="."><plain>TRIAL REGISTRATION: Clinicaltrials.gov NCT00464776 FUNDING: Novartis Pharma AG </plain></SENT>
</text></document>